drugset / Trial / NCT00232258
Nolpitantium Besylate In Patients With Ulcerative Colitis a Double-Blind, Placebo Controlled Efficacy and Safety Study
RandomizedParallel-groupDouble-blindTreatment
Summary
To evaluate the safety and efficacy on clinical symptoms, mucosal histology and endoscopic mucosal appearance of two doses of SR140333B against placebo in patients with mild to moderate ulcerative colitis resistant to treatment with 5-ASA.
Timeline
- Start
- 2005-04
- Primary completion
- 2006-09
- Completion
- 2006-09
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Nolpitantium | Small molecule | 600 mg | — |
| Subject | Nolpitantium | Small molecule | 1800 mg | — |